Morristown Medical Center treats first patient in New Jersey with Edwards’ EVOQUE tricuspid valve replacement
First FDA approved transcatheter therapy for patients with tricuspid regurgitation
MORRISTOWN, NJ (Morris County) – Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using Edwards Lifesciences EVOQUE tricuspid valve replacement, the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
The EVOQUE system is indicated for improving the health status in patients with symptomatic severe TR despite optimal medical therapy, and for whom tricuspid valve replacement is deemed appropriate by a heart care team.
According to National Institutes of Health an estimated 1.6 million people in the U.S. have been diagnosed with TR.
“Until now, there was no available transcatheter treatment options for patients with tricuspid valve disease,” said Robert Kipperman, MD, interventional cardiologist and structural heart disease specialist at Gagnon Cardiovascular Institute’s Valve Center at Morristown Medical Center, part of Atlantic Health System. “We are thrilled to have a new transcatheter valve option which allows patients to feel significantly better by alleviating symptoms such as shortness of breath and can help improve the patients’ quality of life.”
